Attila Nagy
About
Attila Nagy is a scholar working on Molecular Biology, Epidemiology and Oncology.
According to data from OpenAlex, Attila Nagy has authored 78 papers receiving a total of 3.5k indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Molecular Biology, 29 papers in Epidemiology and 28 papers in Oncology. Recurrent topics in Attila Nagy's work include Neuroendocrine Tumor Research Advances (28 papers), Lung Cancer Research Studies (19 papers) and Estrogen and related hormone effects (17 papers). Attila Nagy is often cited by papers focused on Neuroendocrine Tumor Research Advances (28 papers), Lung Cancer Research Studies (19 papers) and Estrogen and related hormone effects (17 papers). Attila Nagy collaborates with scholars based in United States, Hungary and Germany. Attila Nagy's co-authors include Andrew V. Schally, Gábor Halmos, Károly Szepesházi, Patricia Armatis, György B. Halmos, Artur Płonowski, Kate Groot, Magdolna Kovács, Baodong Sun and Gunhild Keller and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Lancet and JNCI Journal of the National Cancer Institute.
In The Last Decade
Attila Nagy
76 papers receiving 3.3k citations
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Attila Nagy United States | 34 | 1.4k | 1.3k | 920 | 648 | 642 | 78 | 3.5k | ||
| Károly Szepesházi United States | 35 | 1.1k 0.8× | 1.2k 0.9× | 821 0.9× | 941 1.5× | 474 0.7× | 96 | 3.1k | ||
| Sharon Shacham United States | 46 | 4.4k 3.2× | 1.4k 1.1× | 236 0.3× | 118 0.2× | 380 0.6× | 221 | 5.8k | ||
| Charles Liebow United States | 20 | 649 0.5× | 326 0.2× | 513 0.6× | 337 0.5× | 173 0.3× | 49 | 1.6k | ||
| Rosemarie Schmandt United States | 32 | 2.7k 2.0× | 1.1k 0.9× | 202 0.2× | 87 0.1× | 334 0.5× | 65 | 4.6k | ||
| H F Lodish United States | 21 | 2.9k 2.1× | 860 0.6× | 180 0.2× | 340 0.5× | 545 0.8× | 23 | 5.3k | ||
| J Fedorko United States | 16 | 1.6k 1.2× | 1.4k 1.1× | 446 0.5× | 136 0.2× | 201 0.3× | 30 | 3.4k | ||
| Lilli Petruzzelli United States | 20 | 3.0k 2.2× | 689 0.5× | 138 0.1× | 680 1.0× | 324 0.5× | 28 | 4.6k | ||
| Silvia Soddu Italy | 44 | 3.8k 2.8× | 2.6k 2.0× | 250 0.3× | 257 0.4× | 575 0.9× | 140 | 5.5k | ||
| Liana Adam United States | 36 | 3.3k 2.4× | 2.0k 1.5× | 108 0.1× | 164 0.3× | 894 1.4× | 50 | 5.2k | ||
| Frédéric Lopez France | 25 | 1.3k 0.9× | 471 0.4× | 480 0.5× | 155 0.2× | 138 0.2× | 46 | 2.6k |
Countries citing papers authored by Attila Nagy
Since
Specialization
Citations
This map shows the geographic impact of Attila Nagy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Attila Nagy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Attila Nagy more than expected).
Fields of papers citing papers by Attila Nagy
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Attila Nagy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Attila Nagy. The network helps show where Attila Nagy may publish in the future.
Co-authorship network of co-authors of Attila Nagy
This figure shows the co-authorship network connecting the top 25 collaborators of Attila Nagy. A scholar is included among the top collaborators of Attila Nagy based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Attila Nagy. Attila Nagy is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Nagy, Attila, et al.. (2024). Knowledge and Self - Reported Practices of Nursing Students regarding the Polycystic Ovarian Syndrome. Mansoura Nursing Journal. 11(3). 0–0.
2.
Keller, Gunhild, et al.. (2006). Effective therapy of experimental human malignant melanomas with a targeted cytotoxic somatostatin analogue without induction of multi-drug resistance proteins. International Journal of Oncology. 28(6). 1507–13.
3.
Engel, J., et al.. (2005). Targeted therapy with a cytotoxic somatostatin analog, AN‐238, inhibits growth of human experimental endometrial carcinomas expressing multidrug resistance protein MDR‐1. Cancer. 104(6). 1312–1321.
4.
Engel, J., et al.. (2005). Targeted cytotoxic bombesin analog AN-215 effectively inhibits experimental human breast cancers with a low induction of multi-drug resistance proteins. Endocrine Related Cancer. 12(4). 999–1009.
5.
Keller, Gunhild, et al.. (2005). Targeted chemotherapy with cytotoxic bombesin analogue AN‐215 can overcome chemoresistance in experimental renal cell carcinomas. Cancer. 104(10). 2266–2274.
6.
Engel, J., et al.. (2005). Experimental therapy of human endometrial cancers with a targeted cytotoxic bombesin analog AN-215: Low induction of multidrug resistance proteins. European Journal of Cancer. 41(12). 1824–1830.
7.
Nagy, Attila & Andrew V. Schally. (2005). Targeting of Cytotoxic Luteinizing Hormone-Releasing Hormone Analogs to Breast, Ovarian, Endometrial, and Prostate Cancers1. Biology of Reproduction. 73(5). 851–859.
8.
Szepesházi, Károly, Andrew V. Schally, Attila Nagy, & Gábor Halmos. (2005). Inhibition of Growth of Experimental Human and Hamster Pancreatic Cancers In Vivo by a Targeted Cytotoxic Bombesin Analog. Pancreas. 31(3). 275–282.
9.
Vadrot, Nathalie, Andrew V. Schally, Attila Nagy, et al.. (2004). Potent induction of apoptosis in human hepatoma cell lines by targeted cytotoxic somatostatin analogue AN-238. Journal of Hepatology. 42(2). 230–237.
10.
Schally, Andrew V., et al.. (2003). Preclinical evaluation of targeted cytotoxic luteinizing hormone-releasing hormone analogue AN-152 in androgen-sensitive and insensitive prostate cancers.. PubMed. 9(12). 4505–13.
11.
Bajo, Ana M., Andrew V. Schally, Gábor Halmos, & Attila Nagy. (2003). Targeted doxorubicin-containing luteinizing hormone-releasing hormone analogue AN-152 inhibits the growth of doxorubicin-resistant MX-1 human breast cancers.. PubMed. 9(10 Pt 1). 3742–8.
12.
Arencibia, José M., Ana M. Bajo, Andrew V. Schally, et al.. (2002). Effective treatment of experimental ES-2 human ovarian cancers with a cytotoxic analog of luteinizing hormone-releasing hormone AN-207. Anti-Cancer Drugs. 13(9). 949–956.
13.
Punt, Cornelis J.A., Attila Nagy, Jean-Yves Douillard, et al.. (2002). Edrecolomab alone or in combination with fluorouracil and folinic acid in the adjuvant treatment of stage III colon cancer: a randomised study. The Lancet. 360(9334). 671–677.
14.
Płonowski, Artur, Andrew V. Schally, Miklós Koppán, et al.. (2001). Inhibition of the UCI-107 human ovarian carcinoma cell line by a targeted cytotoxic analog of somatostatin, AN-238. Cancer. 92(5). 1168–1176.
15.
Szepesházi, Károly, Andrew V. Schally, & Attila Nagy. (1999). Effective treatment of advanced estrogen–independent MXT mouse mammary cancers with targeted cytotoxic LH–RH analogs. Breast Cancer Research and Treatment. 56(3). 265–274.
16.
Nagy, Attila, Andrew V. Schally, Gábor Halmos, et al.. (1998). Synthesis and biological evaluation of cytotoxic analogs of somatostatin containing doxorubicin or its intensely potent derivative, 2-pyrrolinodoxorubicin. Proceedings of the National Academy of Sciences. 95(4). 1794–1799.
17.
Szepesházi, Károly, Andrew V. Schally, Gábor Halmos, et al.. (1996). Effect of a cytotoxic analog of LH-RH (T-98) on the growth of estrogendependent MXT mouse mammary cancers: Correlations between growth characteristics and EGF receptor content of tumors. Breast Cancer Research and Treatment. 40(2). 129–139.
18.
Zarándi, M., Judit Horváth, György B. Halmos, et al.. (1994). Synthesis and biological activities of highly potent antagonists of growth hormone-releasing hormone.. Proceedings of the National Academy of Sciences. 91(25). 12298–12302.
19.
Radulović, Siniša, Attila Nagy, Balázs Szőke, & Andrew V. Schally. (1992). Cytotoxic analog of somatostatin containing methotrexate inhibits growth of MIA PaCa-2 human pancreatic cancer xenografts in nude mice. Cancer Letters. 62(3). 263–271.
20.
Szepesházi, Károly, Andrew V. Schally, Attila Juhász, Attila Nagy, & Tamás Janáky. (1992). Effect of luteinizing hormone-releasing hormone analogs containing cytotoxic radicals on growth of estrogen-independent MXT mouse mammary carcinoma in vivo. Anti-Cancer Drugs. 3(2). 109–116.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Károly Szepesházi Breakdown of academic impact, for papers by Sharon Shacham Breakdown of academic impact, for papers by Charles Liebow Breakdown of academic impact, for papers by Rosemarie Schmandt Breakdown of academic impact, for papers by H F Lodish Breakdown of academic impact, for papers by J Fedorko Breakdown of academic impact, for papers by Lilli Petruzzelli Breakdown of academic impact, for papers by Silvia Soddu Breakdown of academic impact, for papers by Liana Adam Breakdown of academic impact, for papers by Frédéric Lopez